Changes in the p53 status lead to altered efficacy of classical therapies, which is relevant because a p53 mutation can occur in up to half of CRC cases [132], [133], but most cancer cells tend to initially have high levels of p53 [130]. The gene discussed is TP53; the disease is colorectal carcinoma.